Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Neoplasm Malignant Female
- Breast Neoplasms, Triple-Negative
- Radiotherapy Side Effect
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Open label phase I, dose escalation trial for patients with triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated with residual disease (after neoadjuvant chemotherapy).
Open label phase I, dose escalation trial for patients with triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated with residual disease (after neoadjuvant chemotherapy).
Tracking Information
- NCT #
- NCT03109080
- Collaborators
- AstraZeneca
- Investigators
- Study Director: Youlia KIROVA, MD Institut Curie
Get Well Soon